Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

被引：21
|
作者：
Barroso-Sousa, Romualdo
Li, Tianyu
Reddy, Sangeetha
Emens, Leisha A.
Overmoyer, Beth
Lange, Paulina
Dilullo, Molly K.
Attaya, Victoria
Kimmel, Jeffrey
Winer, Eric P.
Mittendorf, Elizabeth A.
Tayob, Nabihah
Tolaney, Sara M.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS2-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-10
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax plus fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC)
    Lindeman, Geoffrey J.
    Fernando, Tharu M.
    Bowen, Rebecca
    Chang, Ching-Wei
    Desai, Rupal
    Gupta, Kushagra
    Flechais, Aulde
    Wilson, Timothy R.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [32] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
  • [33] A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
    Martin Schuler
    Ahmad Awada
    Philipp Harter
    Jean Luc Canon
    Kurt Possinger
    Marcus Schmidt
    Jacques De Grève
    Patrick Neven
    Luc Dirix
    Walter Jonat
    Matthias W. Beckmann
    Jochen Schütte
    Peter A. Fasching
    Nina Gottschalk
    Tatiana Besse-Hammer
    Frank Fleischer
    Sven Wind
    Martina Uttenreuther-Fischer
    Martine Piccart
    Nadia Harbeck
    Breast Cancer Research and Treatment, 2012, 134 : 1149 - 1159
  • [34] Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
    Ni, M.
    Zhou, L.
    Lu, Y.
    Zhang, L.
    Li, X.
    Chen, M.
    Yang, A.
    Zhang, L.
    Xu, F.
    Yuan, Z.
    Wang, S.
    Shi, Y.
    An, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1490 - S1490
  • [35] Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
    Takada, Masahiro
    Yoshimura, Michio
    Kotake, Takeshi
    Kawaguchi, Kosuke
    Uozumi, Ryuji
    Kataoka, Masako
    Kato, Hironori
    Yoshibayashi, Hiroshi
    Suwa, Hirofumi
    Tsuji, Wakako
    Yamashiro, Hiroyasu
    Suzuki, Eiji
    Torii, Masae
    Yamada, Yosuke
    Kataoka, Tatsuki
    Ishiguro, Hiroshi
    Morita, Satoshi
    Toi, Masakazu
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [36] Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
    Masahiro Takada
    Michio Yoshimura
    Takeshi Kotake
    Kosuke Kawaguchi
    Ryuji Uozumi
    Masako Kataoka
    Hironori Kato
    Hiroshi Yoshibayashi
    Hirofumi Suwa
    Wakako Tsuji
    Hiroyasu Yamashiro
    Eiji Suzuki
    Masae Torii
    Yosuke Yamada
    Tatsuki Kataoka
    Hiroshi Ishiguro
    Satoshi Morita
    Masakazu Toi
    Scientific Reports, 12
  • [37] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Misato Okazaki
    Yoshiya Horimoto
    Masahiko Tanabe
    Yuko Ichikawa
    Emi Tokuda
    Atsushi Arakawa
    Toshiyuki Kobayashi
    Mitsue Saito
    Medical Oncology, 2018, 35
  • [38] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [39] Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial
    Barton, J. H.
    Shih, K. C.
    Raefsky, E.
    Haines, D. W.
    Strike, B.
    Hainsworth, J. D.
    Burris, H. A.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).
    Gil-Martin, Marta
    Pardo, Patricia Gomez
    Lopez-Tarruella, Sara
    Manso, Luis
    Perez-Fidalgo, Jose Alejandro
    Ademuyiwa, Foluso Olabisi
    Mayer, Ingrid A.
    Pluard, Timothy J.
    Garcia, Maria Martinez
    Kaufman, Peter A.
    Vandat, Linda T.
    Hooftman, Leon W.
    Romagnoli, Barbara
    Hernando, Cristina
    Weilbaecher, Katherine N.
    Ciruelos, Eva M.
    Martin, Miguel
    Simon, Sonia Pernas
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345